17 February

Lancet - Hypertension https://www.thelancet.com/collection/001542

• 07:13
  [Articles] Xanthine oxidase inhibition and white matter hyperintensity progression following ischaemic stroke and transient ischaemic attack (XILO-FIST): a multicentre, double-blinded, randomised, placebo-controlled trial - Jesse Dawson, Michele Robertson, David Alexander Dickie, Phillip Bath, Kirsten Forbes, Terence Quinn, Niall M. Broomfield, Krishna Dani, Alex Doney, Graeme Houston, Kennedy R. Lees, Keith W. Muir, Allan Struthers, Matthew Walters, Mark Barber, Ajay Bhalla, Alan Cameron, Alexander Dyker, Paul Guyler, Ahamad Hassan, Mark T. Kearney, Breffni Keegan, Sekaran Lakshmanan, Mary Joan Macleod, Marc Randall, Louise Shaw, Ganesh Subramanian, David Werring, Alex (...) Lancet - Hypertension
  Allopurinol use did not reduce WMH progression in people with recent ischaemic stroke or TIA and is unlikely to reduce the risk of stroke in unselected people. (eClinicalMedicine 57, (2023))

30 January

Lancet - Hypertension https://www.thelancet.com/collection/001542

• 07:13
  [Articles] Mean systolic blood pressure above the control threshold in people with treated uncontrolled hypertension: a pooled, cross-sectional analysis of 55 national health surveys - Rodrigo M. Carrillo-Larco, Wilmer Cristobal Guzman-Vilca, Xiaolin Xu, Antonio Bernabe-Ortiz Lancet - Hypertension
  Stronger interventions to improve and secure access to effective management are needed in most countries and specific groups, to reach hypertension control in people with hypertension already receiving antihypertensive medication. (eClinicalMedicine 57, (2023))

14 December

Lancet - Hypertension https://www.thelancet.com/collection/001542

• 14:42
  [Articles] Factors associated with the uptake of national essential public health service package for hypertension and type-2 diabetes management in China's primary health care system: a mixed-methods study - Shangzhi Xiong, Wei Jiang, Ruilin Meng, Chi Hu, Hui Liao, Yongchen Wang, Chang Cai, Xinyi Zhang, Pengpeng Ye, Yanqiuzi Ma, Tingzhuo Liu, Dandan Peng, Jiajuan Yang, Li Gong, Qiujun Wang, David Peiris, Limin Mao, Maoyi Tian Lancet - Hypertension
  The study findings provided recommendation for future PHC system strengthening, including improving the quality of NEPHSP delivery, facilitating resource-sharing across health facilities, establishing integrated care systems, and exploring mechanisms for better cross-sectorial engagement in (...) (The Lancet Regional Health – Western Pacific 31, (2023))

5 December

Lancet - Hypertension https://www.thelancet.com/collection/001542

• 13:40
  [Articles] Ethnic differences in hypertension management, medication use and blood pressure control in UK primary care, 2006–2019: a retrospective cohort study - Sophie V. Eastwood, Alun D. Hughes, Laurie Tomlinson, Rohini Mathur, Liam Smeeth, Krishnan Bhaskaran, Nishi Chaturvedi Lancet - Hypertension
  We demonstrate that antihypertensive initiation does not vary by ethnicity, but subsequent BP control was notably lower among people of African/African Caribbean ethnicity, potentially associated with being less likely to remain on regular treatment. A nationwide strategy to understand and (...) (The Lancet Regional Health – Europe 25, (2023))

1 December

Lancet - Hypertension https://www.thelancet.com/collection/001542

• 00:00
  [Articles] The burden of cardiovascular disease attributable to high systolic blood pressure across China, 2005–18: a population-based study - Xue Cao, Zhenping Zhao, Yuting Kang, Yixin Tian, Yuxin Song, Limin Wang, Linfeng Zhang, Xin Wang, Zuo Chen, Congyi Zheng, Lu Tian, Peng Yin, Yuehui Fang, Mei Zhang, Yuna He, Zugui Zhang, William S Weintraub, Maigeng Zhou, Zengwu Wang, China Burden of Disease Attributable to Risk Factors Collaborative Group Lancet - Hypertension
  The deaths and YLLs for cardiovascular disease attributable to high systolic blood pressure in China increased between 2005 and 2018, and age-standardised cardiovascular disease mortality rates decreased in the same timeframe. Our findings could help policy makers in promoting blood pressure (...) (The Lancet Public Health 7, 12 (2022))

7 November

Lancet - Hypertension https://www.thelancet.com/collection/001542

• 22:10
  [Articles] Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trial - Markus P Schlaich, Marc Bellet, Michael A Weber, Parisa Danaietash, George L Bakris, John M Flack, Roland F Dreier, Mouna Sassi-Sayadi, Lloyd P Haskell, Krzysztof Narkiewicz, Ji-Guang Wang, PRECISION investigators Lancet - Hypertension
  In patients with resistant hypertension, aprocitentan was well tolerated and superior to placebo in lowering blood pressure at week 4 with a sustained effect at week 40. (The Lancet 400, 10367 (2022))

4 November

Lancet - Hypertension https://www.thelancet.com/collection/001542

• 07:12
  [Articles] Digital redesign of hypertension management with practice and patient apps for blood pressure control (PIA study): a cluster-randomised controlled trial in general practices - Frauke Leupold, Arian Karimzadeh, Thorben Breitkreuz, Fabian Draht, Kerstin Klidis, Thomas Grobe, Birgitta Weltermann Lancet - Hypertension
  The PIA redesign of care processes improved BP in an outcome-relevant way. Prospectively, it may constitute an important model for hypertension care in Germany. (eClinicalMedicine 55, (2023))

1 November

Lancet - Hypertension https://www.thelancet.com/collection/001542

• 00:00
  [Articles] Individualising intensive systolic blood pressure reduction in hypertension using computational trial phenomaps and machine learning: a post-hoc analysis of randomised clinical trials - Evangelos K Oikonomou, Erica S Spatz, Marc A Suchard, Rohan Khera Lancet - Hypertension
  By use of machine learning to define an individual's personalised benefit through phenotypic representations of clinical trials, we created a practical tool for individualising the selection of intensive versus standard systolic blood pressure control in patients without and with type 2 (...) (The Lancet Digital Health 4, 11 (2022))

28 October

Lancet - Hypertension https://www.thelancet.com/collection/001542

• 08:00
  [Articles] Intensive blood pressure control after endovascular thrombectomy for acute ischaemic stroke (ENCHANTED2/MT): a multicentre, open-label, blinded-endpoint, randomised controlled trial - Pengfei Yang, Lili Song, Yongwei Zhang, Xiaoxi Zhang, Xiaoying Chen, Yunke Li, Lingli Sun, Yingfeng Wan, Laurent Billot, Qiang Li, Xinwen Ren, Hongjian Shen, Lei Zhang, Zifu Li, Pengfei Xing, Yongxin Zhang, Ping Zhang, Weilong Hua, Fang Shen, Yihan Zhou, Bing Tian, Wenhuo Chen, Hongxing Han, Liyong Zhang, Chenghua Xu, Tong Li, Ya Peng, Xincan Yue, Shengli Chen, Changming Wen, Shu Wan, Congguo Yin, Ming Wei, Hansheng Shu, Guangxian Nan, Sheng Liu, Wenhua Liu, Yiling Cai, Yi Sui, Maohua Chen, Yu Zhou, Qiao Zuo, Dongwei Dai, Rui Zhao, Qiang Li, Qinghai Huang, Yi Xu, Benqiang Deng, Tao Wu, (...) Lancet - Hypertension
  Intensive control of systolic blood pressure to lower than 120 mm Hg should be avoided to prevent compromising the functional recovery of patients who have received endovascular thrombectomy for acute ischaemic stroke due to intracranial large-vessel (...) (The Lancet 400, 10363 (2022))

12 October

Lancet - Hypertension https://www.thelancet.com/collection/001542

• 00:30
  [Articles] Cardiovascular outcomes in adults with hypertension with evening versus morning dosing of usual antihypertensives in the UK (TIME study): a prospective, randomised, open-label, blinded-endpoint clinical trial - Isla S Mackenzie, Amy Rogers, Neil R Poulter, Bryan Williams, Morris J Brown, David J Webb, Ian Ford, David A Rorie, Greg Guthrie, J W Kerr Grieve, Filippo Pigazzani, Peter M Rothwell, Robin Young, Alex McConnachie, Allan D Struthers, Chim C Lang, Thomas M MacDonald, TIME Study Group Lancet - Hypertension
  Evening dosing of usual antihypertensive medication was not different from morning dosing in terms of major cardiovascular outcomes. Patients can be advised that they can take their regular antihypertensive medications at a convenient time that minimises any undesirable (...) (The Lancet 400, 10361 (2022))

27 September

Lancet - Hypertension https://www.thelancet.com/collection/001542

• 19:15
  [Articles] Machine learning for classification of hypertension subtypes using multi-omics: A multi-centre, retrospective, data-driven study - Parminder S. Reel, Smarti Reel, Josie C. van Kralingen, Katharina Langton, Katharina Lang, Zoran Erlic, Casper K. Larsen, Laurence Amar, Christina Pamporaki, Paolo Mulatero, Anne Blanchard, Marek Kabat, Stacy Robertson, Scott M. MacKenzie, Angela E. Taylor, Mirko Peitzsch, Filippo Ceccato, Carla Scaroni, Martin Reincke, Matthias Kroiss, Michael C. Dennedy, Alessio Pecori, Silvia Monticone, Jaap Deinum, Gian Paolo Rossi, Livia Lenzini, John D. McClure, Thomas Nind, Alexandra Riddell, Anthony Stell, Christian Cole, Isabella Sudano, Cornelia Prehn, Jerzy Adamski, Anne-Paule Gimenez-Roqueplo, (...) Lancet - Hypertension
  We have developed a ML pipeline to distinguish different EHT subtypes from PHT using multi-omics data. This innovative approach to stratification is an advancement towards the development of a diagnostic tool for EHT patients, significantly increasing testing throughput and accelerating (...) (eBioMedicine 84, (2022))

17 September

Lancet - Hypertension https://www.thelancet.com/collection/001542

• 21:41
  [Viewpoint] Frontier digital technology: Transforming noncommunicable disease prevention among youth - Thuong Nguyen Hai, Laura Meyer, Helen McGuire, Hanh Nguyen Thi Hong, Linh Nguyen Thi Lancet - Hypertension
  Early adolescence is a pivotal moment when negative influences can cause long-term habits and adverse consequences, even if health effects manifest later in life. Researchers estimate 70% of premature deaths in adults can be linked to behaviors that start in adolescence.1 As noncommunicable (...) (The Lancet Regional Health – Western Pacific 29, (2022))

6 September

Lancet - Hypertension https://www.thelancet.com/collection/001542

• 19:13
  [Articles] Machine learning integration of multimodal data identifies key features of blood pressure regulation - Panayiotis Louca, Tran Quoc Bao Tran, Clea du Toit, Paraskevi Christofidou, Tim D. Spector, Massimo Mangino, Karsten Suhre, Sandosh Padmanabhan, Cristina Menni Lancet - Hypertension
  We show that an integrated analysis of omics, biochemical and dietary data improves our understanding of their in-between relationships and expands the range of potential biomarkers for blood pressure. Our results point to potentially key biological pathways to be prioritised for mechanistic (...) (eBioMedicine 84, (2022))

1 August

Lancet - Hypertension https://www.thelancet.com/collection/001542

• 00:00
  [Articles] Hypertension in stroke survivors and associations with national premature stroke mortality: data for 2·5 million participants from multinational screening campaigns - Queran Lin, Tingxi Ye, Pengpeng Ye, Claudio Borghi, Suzie Cro, Albertino Damasceno, Nadia Khan, Peter M Nilsson, Dorairaj Prabhakaran, Agustin Ramirez, Markus P Schlaich, Aletta E Schutte, George Stergiou, Michael A Weber, Thomas Beaney, Neil R Poulter Lancet - Hypertension
  Blood pressure control remains suboptimal worldwide among people with a history of stroke. National estimates of blood pressure management reflect national premature stroke mortality sufficiently to prompt policy makers to promote blood pressure screening and (...) (The Lancet Global Health 10, 8 (2022))

23 July

Lancet - Hypertension https://www.thelancet.com/collection/001542

• 00:30
  [Comment] Blood pressure control according to type 2 diabetes status - Luis M Ruilope, Gema Ruiz-Hurtado Lancet - Hypertension
  The control of arterial hypertension is mandatory in people with and without type 2 diabetes. The Article by the Blood Pressure Lowering Treatment Trialists' Collaboration (BPLTTC), published in The Lancet Diabetes & Endocrinology.1 One-stage individual participant-level data meta-analysis (...) (The Lancet Diabetes & Endocrinology 10, 9 (2022))
• 00:30
  [Articles] Blood pressure-lowering treatment for prevention of major cardiovascular diseases in people with and without type 2 diabetes: an individual participant-level data meta-analysis - Milad Nazarzadeh, Zeinab Bidel, Dexter Canoy, Emma Copland, Derrick A Bennett, Abbas Dehghan, George Davey Smith, Rury R Holman, Mark Woodward, Ajay Gupta, Amanda I Adler, Malgorzata Wamil, Naveed Sattar, William C Cushman, Richard J McManus, Koon Teo, Barry R Davis, John Chalmers, Carl J Pepine, Kazem Rahimi, Blood Pressure Lowering Treatment Trialists' Collaboration Lancet - Hypertension
  Although the relative beneficial effects of blood pressure reduction on major cardiovascular events were weaker in participants with type 2 diabetes than in those without, absolute effects were similar. The difference in relative risk reduction was not related to the baseline blood pressure or (...) (The Lancet Diabetes & Endocrinology 10, 9 (2022))

14 July

Lancet - Hypertension https://www.thelancet.com/collection/001542

• 19:17
  [Articles] Exercise-derived peptide protects against pathological cardiac remodeling - Anwen Yin, Ruosen Yuan, Qingqing Xiao, Weifeng Zhang, Ke Xu, Xiaoxiao Yang, Wentao Yang, Lei Xu, Xia Wang, Fei Zhuang, Yi Li, Zhaohua Cai, Zhe Sun, Bin Zhou, Ben He, Linghong Shen Lancet - Hypertension
  The results provide new insights into exercise-afforded cardioprotection in pathological cardiac remodeling and highlight the therapeutic potential of CCDC80tide in heart failure treatment. (eBioMedicine 82, (2022))

13 May

Lancet - Hypertension https://www.thelancet.com/collection/001542

• 07:14
  [Articles] Variability independent of mean blood pressure as a real-world measure of cardiovascular risk - Joseph E. Ebinger, Matthew Driver, David Ouyang, Patrick Botting, Hongwei Ji, Mohamad A. Rashid, Ciantel A. Blyler, Natalie A. Bello, Florian Rader, Teemu J. Niiranen, Christine M. Albert, Susan Cheng Lancet - Hypertension
  VIM derived from clinically generated data remains associated with adverse cardiovascular outcomes and represents a risk marker beyond mean BP, including in important demographic and clinical subgroups. The demonstrated prognostic ability of VIM derived from non-standardized BP readings (...) (eClinicalMedicine 48, (2022))
• 07:14
  [Articles] Effect of moderate to high intensity aerobic exercise on blood pressure in young adults: The TEPHRA open, two-arm, parallel superiority randomized clinical trial - Wilby Williamson, Adam James Lewandowski, Odaro John Huckstep, Winok Lapidaire, Alexander Ooms, Cheryl Tan, Afifah Mohamed, Maryam Alsharqi, Mariane Bertagnolli, William Woodward, Cameron Dockerill, Annabelle McCourt, Yvonne Kenworthy, Holger Burchert, Aiden Doherty, Julia Newton, Henner Hanssen, John Kennedy Cruickshank, Richard McManus, Jane Holmes, Chen Ji, Sharon Love, Elena Frangou, Colin Everett, Melvyn Hillsdon, Helen Dawes, Charlie Foster, Paul (...) Lancet - Hypertension
  Exercise is advised for young adults with elevated blood pressure, but no trials have investigated efficacy at this age. We aimed to determine whether aerobic exercise, self-monitoring and motivational coaching lowers blood pressure in this (...) (eClinicalMedicine 48, (2022))

30 April

Lancet - Hypertension https://www.thelancet.com/collection/001542

• 00:30
  [Articles] A village doctor-led multifaceted intervention for blood pressure control in rural China: an open, cluster randomised trial - Yingxian Sun, Jianjun Mu, Dao Wen Wang, Nanxiang Ouyang, Liying Xing, Xiaofan Guo, Chunxia Zhao, Guocheng Ren, Ning Ye, Ying Zhou, Jun Wang, Zhao Li, Guozhe Sun, Ruihai Yang, Chung-Shiuan Chen, Jiang He, CRHCP Study Group Lancet - Hypertension
  Compared with enhanced usual care, village doctor-led intervention resulted in statistically significant improvements in blood pressure control among rural residents in China. This feasible, effective, and sustainable implementation strategy could be scaled up in rural China and other (...) (The Lancet 399, 10339 (2022))